HALCION

This brand name is authorized in United States. It is also authorized in Austria, Estonia, Finland, Germany, Hong Kong SAR China, Ireland, Japan, Lithuania, Mexico, Spain.

Active ingredients

The drug HALCION contains one active pharmaceutical ingredient (API):

1	Triazolam UNII 1HM943223R - TRIAZOLAM
	Triazolam is a short-acting benzodiazepine with anticonvulsant anxiolytic, sedative, muscle relaxant and amnesic properties. It is used as a hypnotic in the short-term management of insomnia.
	Read more about Triazolam

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HALCION Tablet	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05CD05	Triazolam	N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives → N05CD Benzodiazepine derivatives
Discover more medicines within N05CD05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	02187391, 06497941
EE	Ravimiamet	1037359, 1761498
ES	Centro de información online de medicamentos de la AEMPS	58118
FI	Lääkealan turvallisuus- ja kehittämiskeskus	199133
HK	Department of Health Drug Office	00495
IE	Health Products Regulatory Authority	27340, 27529
JP	医薬品医療機器総合機構	1124007F1020, 1124007F2026
LT	Valstybinė vaistų kontrolės tarnyba	1014878, 1067196, 1081944, 1087823
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	89847
US	FDA, National Drug Code	0009-0017